CA2571519A1 - Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant - Google Patents
Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant Download PDFInfo
- Publication number
- CA2571519A1 CA2571519A1 CA002571519A CA2571519A CA2571519A1 CA 2571519 A1 CA2571519 A1 CA 2571519A1 CA 002571519 A CA002571519 A CA 002571519A CA 2571519 A CA2571519 A CA 2571519A CA 2571519 A1 CA2571519 A1 CA 2571519A1
- Authority
- CA
- Canada
- Prior art keywords
- water
- propellant gas
- aerosol suspension
- amino
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
The invention relates to propellant formulations containing at least one suspended active ingredient which contains chemically bound water, water, and the propellant TG 227 or TG 134 a.
Description
88307pct The invention relates to pressurised gas preparations for mctered-dose aerosols wherein a pharmaceutical composition is formulated as a suspension in TG 227 ea (1,1,1,2,3,3,3-heptafluoropropane) or TG 134 a(1,1,1,2-tetrafluoroethane) as propellant, and the use thereof for preparing a pharmaceutical composition. It preferably relates to an inhalable aerosol.
Prior art Ever since the public discussions on the ozone-damaging potential of certain chlorofluorocarbons there has been intensive work in the field of alternative propellants for pharmaceutical metered-dose aerosols. It has been known since the early 1990s that the propellant gases TG 227 ea or TG 134 a may be used as alternative propellant gases for aerosols.
It has now been found that, surprisingly, propellant gas formulations with suspended particles of active substance and TG 227 ea or TG 134 a as propellant can be stabilised if the propellant gas or propellant gas mixture contains a certain amount of water.
Detailed description of the invention For the propellant formulations according to the invention TG 227 ea and/or TG
134 a are used as propellant gases, optionally in admixture with one or more other propellant gases, preferably selected from among propane, butane, pentane, dimethylether, CHCIF2, CHZF,, CF3CH3, isobutane, isopentane and neopentane.
Preferred suspensions according to the invention are those which contain as propellant gas only TG 227 ea or only TG 134 a.
If a mixture of the propellant gases TG 227 ea and TG 134a is used in the suspension formulations according to the invention, the proportions by weight in which these two propellant gas components may be used may be freely variable, although TG 227 ea must be present.
In mixtures with one or more other propellant gases, selected from among propane, butane, pentane, dimethylether, CHCIF1, CH~F-7, CF3CH3, isobutane, isopentane and neopentane, the proportion of this other propellant gas component is preferably less than 60 %, preferably below 40% and most preferably less than 30%.
Prior art Ever since the public discussions on the ozone-damaging potential of certain chlorofluorocarbons there has been intensive work in the field of alternative propellants for pharmaceutical metered-dose aerosols. It has been known since the early 1990s that the propellant gases TG 227 ea or TG 134 a may be used as alternative propellant gases for aerosols.
It has now been found that, surprisingly, propellant gas formulations with suspended particles of active substance and TG 227 ea or TG 134 a as propellant can be stabilised if the propellant gas or propellant gas mixture contains a certain amount of water.
Detailed description of the invention For the propellant formulations according to the invention TG 227 ea and/or TG
134 a are used as propellant gases, optionally in admixture with one or more other propellant gases, preferably selected from among propane, butane, pentane, dimethylether, CHCIF2, CHZF,, CF3CH3, isobutane, isopentane and neopentane.
Preferred suspensions according to the invention are those which contain as propellant gas only TG 227 ea or only TG 134 a.
If a mixture of the propellant gases TG 227 ea and TG 134a is used in the suspension formulations according to the invention, the proportions by weight in which these two propellant gas components may be used may be freely variable, although TG 227 ea must be present.
In mixtures with one or more other propellant gases, selected from among propane, butane, pentane, dimethylether, CHCIF1, CH~F-7, CF3CH3, isobutane, isopentane and neopentane, the proportion of this other propellant gas component is preferably less than 60 %, preferably below 40% and most preferably less than 30%.
The active substances used are preferably active substances which incorporate or bind one or more water molecules in their particle structure. The water is not only physically mixed with the particles of active substance. Preferably the particles of active substance are crystals and the water is water of crystallisation or complex-bound water or water which is otherwise chemically bound, e.g. hydrates. This form of water incorporation is hereinafter also referred to as chemically bound water. In these cases the water generally also affects the crystalline structure of the active substance molecule.
Compounds which are effective by inhalation are preferably used, with the result that the suspension formulations according to the invention are preferably intended for inhalation.
Particularly preferred in this context are pharmaceutical compositions selected from among the anticholinergics, betamimetics, steroids, phosphodiesterase IV inhibitors, antagonists and EGFR-kinase inhibitors, antiallergics, ergot alkaloid derivatives, triptanes, CGRP antagonists, phosphodiesterase-V inhibitors, and combinations of active substances of this kind, e.g. betamimetics plus anticholinergics or betamimetica plus antiallergics. In the case of combinations at least one of the active substances contains chemically bound water.
Anticholinergic-containing active substances are preferably used, as monopreparations or in the form of combined preparations.
The following are specific examples of the active ingredients or the salts thereof:
Anticholinergics to be used are preferably selected from among tiotropium bromide, oxitropium bromide, flutropium bromide, ipratropium bromide, glycopyrronium salts, trospium chloride, tolterodine, tropenol 2,2-diphenylpropionate methobromide, scopine 2,2-diphenylpropionate methobromide, scopine 2-fluoro-2,2-diphenylacetate-methobromide, tropenol 2-fluoro-2,2-diphenylacetate-methobromide, tropenol 3,3',4,4'-tetrafluorobenzilate methobromide, scopine 3,3',4,4'-tetrafluorobenzilate methobromide, tropenol 4,4'-difluorobenzilate methobromide, scopine 4,4'-difluorobenzilate methobromide, tropenol 3,3'-difluorobenzilate methobromide, scopine 3,3'-difluorobenzilate methobromide, tropenol 9-hydroxy-fluorene-9-carboxylate methobrornide, tropenol 9-fluoro-fluorene-9-carboxylate nlethobromide, scopine 9-hydroxy-fluorene-9-carboxylate methobromide, scopine 9-fluoro-fluorene-9-carboxyl ate methobromide, tropenol 9-methyl-fluorene-9-carboxylate methobromide, scopine 9-methyl-fluorene-9-carboxylate methobromide, cyclopropyltropine benzilate methobromide, 2,2-diphenylpropionate cyclopropyltropine methobromide, cyclopropyltropine 9-hydroxy-xanthene-9-carboxylate methobromide, cyclopropyltropine 9-methyl-fluorene-9-carboxylate methobromide, cyclopropyltropine 9-methyl-xanthene-9-carboxylate methobromide, cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide, methyl cyclopropyltropine 4,4'-difluorobenzilate methobromide, tropenol 9-hydroxy-xanthene-9-carboxylate methobromide, scopine 9-hydroxy-xanthene-9-carboxylate methobromide, tropenol 9-methyl-xanthene-9-carboxylate methobromide, scopine 9-methyl-xanthene-9-carboxylate methobromide, tropenol 9 -ethyl -x anthene- 9- carboxyl ate methobromide, tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide and scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the solvates and/or hydrates thereof.
Betamimetics which may be used are preferably selected from among albuterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reprotcrol, rimiterol, ritodrine, salmeterol, salmefamol, soterenot, sulphonterol, tiaramide, terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3 -(4- {6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzenesulphonamide, 5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-lH-quinolin-2-one, 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulphonyl}ethyl]-ainino}ethyl]-2(3H)-benzothiazolone, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-inethyl-2-butylamino]ethanol, 1-[3-(4-methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-3o butylamino}ethanol, 5-hydroxy-8-(i-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-orie, 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol and 1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.
Steroids which may be used are preferably selected from among prednisolone, prednisone, butixocortpropionate, RPR-106541, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rotleponide, ST-126, dexamethasone, (S)-fluoromethyl 6a,9a-difluoro-l7a-[(2-furanylcarbonyl)oxy]-11(3-hydroxy-16a-methyl-3-oxo-androsta-1,4-diene-17(3-carbothionate, (S)-(2-oxo-tetrahydro-furan-3S-yl) 6a,9a-difluoro-11(3-hydroxy-16a-methyl-3-oxo-l7a-propionyloxy-androsta-1,4-diene-17(3-carbothionate and etiprednol-dichloroacetate (BNP-166), optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.
PDE IV inhibitors which may be used are preferably selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), CP-325,366, BY343, D-4396 (Sch-351591), AWD-12-281 (GW-842470), N-(3,5-dichloro-l-oxo-pyridin-4-yl)-4-difluoromethoxy-cyclopropylmethoxybenzamide, NCS-613, pumafentine, (-)p-[(4aR*, I ObS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[s] [ 1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide, (R)-(+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone, 3-(cyclopentyloxy-4-methoxyphenyl)-1-(4-N'-[N-2-cyano-S-methyl-isothioureido]benzyl)-2-pyrrolidone, cis[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-l-carboxylic acid], 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-one, cis[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-ol], (R)-(+)-ethyl[4-(3-cyelopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate, (S)-(-)-ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate, CDP840, Bay-198004, D-4418, PD-168787, T-440, T-2585, arofyllin, atizoram, V-11294A, C1-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine and 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.
LTD4-antagonists which may be used are preferably selected from among montelukast, 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2- hydroxy-2-propyl)phenyl)thio)methylcyclopropane-acetic acid, 1-(((1(R)-3(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-l-methylethyl)phenyl)propyl)thio)-methyl)cyclopropane-acetic acid, pranlukast, zafirlukast, [2-[[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid, MCC-847 (ZD-3523), MN-001, MEN-(LM-1507), VUF-5078, VUF-K-8707 and L-733321, optionally in the form of the racemates, cnantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.
EGFR-kinase inhibitors which may be used are preferably selected from among cetuximab, 5 trastuzumab, ABX-EGF, Mab ICR-62, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-am] no]-1-oxo-2-buten-l-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-( {4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-1-oxo-2-buten-l-yl} amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-rnethoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-l-yl}amino)-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6- { [4-(N,N-dimethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6,7-bis-(2-methoxy-ethoxy)-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-(4-hydroxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidine, 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-l-yl]amino}-7-ethoxy-quinoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-rnethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperidin-1-yl]-ethoxy} -7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-3-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-acetylamino-ethyl)-piperi din-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-ethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-l-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)am] no]-6- { 1-[(piperidin-1-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-ethansulphonylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(tetrahydropyran-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4- {N-[(piperidin-l-yl)carbonyl]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxopyrrolidin-l-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(1-acetyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7(2-methoxy-ethoxy)-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(N-methyl-N-2-methoxyethyl-amino)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-ethyl-piperi din-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, and 4-[(3-chloro-4-fluoro-phenyl)amino]-6- { 1-[(2-methoxyethyl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts thereof, the solvates and/or hydrates thereof.
By acid addition salts with pharmacologically acceptable acids which the compounds may be capable of forming are meant, for example, salts selected from among the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably the hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate.
Examples of antiallergics are: disodium cromoglycate, nedocromil.
Examples of ergot alkaloids are: dihydroergotamine, ergotamine.
Examples of substances suitable for inhalation include pharmaceutical compositions containing the above-mentioned active substances, and the salts and esters thereof and combinations of these active substances, salts and esters thereo~
The proportion of suspended drug in the finished preparation is between 0.001 and 5 %, preferably 0.005 to 3 %, particularly 0.01 to 2 %. Surface-active substances are added in amounts of from 0.01 to 10 %, preferably 0.05 to 5 %, particularly 0.05 to 3 %
(% = percent by weight).
In the case of ipratropium bromide monohydrate the suspensions according to the invention preferably contain between 0.001 to 1%, particularly 0.005 to 0.5%
ipratropium. Particularly preferred according to the invention are suspensions which contain 0.01 to 0.
1% ipratropium.
In the case of salbutamol and the salts thereof the suspensions according to the invention preferably contain between 0.005 to 5%, particularly 0.025 to 2.5% salbutamol.
Particularly preferred according to the invention are suspensions which contain 0.05 to 1%
salbutamol.
In the case of tiotropium bromide monohydrate the suspensions according to the invention preferably contain between 0.001 to 1 /o, particularly 0.0012 to 0,8%
tiotropium. Preferred according to the invention are suspensions which contain 0.002 to 0.5%, particularly preferably 0.008 to 0.4% tiotropium.
By all the active substances, e.g. tiotropium or ipratropium, is meant in each case the free ammonium cation. The propellant gas suspensions according to the invention are characterised in that they contain tiotropium or ipratropium in the form of the crystalline monohydrates. Accordingly, the present invention preferably relates to suspensions which contain crystalline tiotropium bromide monohydrate or ipratropium bromide monohydrate.
Compounds which are effective by inhalation are preferably used, with the result that the suspension formulations according to the invention are preferably intended for inhalation.
Particularly preferred in this context are pharmaceutical compositions selected from among the anticholinergics, betamimetics, steroids, phosphodiesterase IV inhibitors, antagonists and EGFR-kinase inhibitors, antiallergics, ergot alkaloid derivatives, triptanes, CGRP antagonists, phosphodiesterase-V inhibitors, and combinations of active substances of this kind, e.g. betamimetics plus anticholinergics or betamimetica plus antiallergics. In the case of combinations at least one of the active substances contains chemically bound water.
Anticholinergic-containing active substances are preferably used, as monopreparations or in the form of combined preparations.
The following are specific examples of the active ingredients or the salts thereof:
Anticholinergics to be used are preferably selected from among tiotropium bromide, oxitropium bromide, flutropium bromide, ipratropium bromide, glycopyrronium salts, trospium chloride, tolterodine, tropenol 2,2-diphenylpropionate methobromide, scopine 2,2-diphenylpropionate methobromide, scopine 2-fluoro-2,2-diphenylacetate-methobromide, tropenol 2-fluoro-2,2-diphenylacetate-methobromide, tropenol 3,3',4,4'-tetrafluorobenzilate methobromide, scopine 3,3',4,4'-tetrafluorobenzilate methobromide, tropenol 4,4'-difluorobenzilate methobromide, scopine 4,4'-difluorobenzilate methobromide, tropenol 3,3'-difluorobenzilate methobromide, scopine 3,3'-difluorobenzilate methobromide, tropenol 9-hydroxy-fluorene-9-carboxylate methobrornide, tropenol 9-fluoro-fluorene-9-carboxylate nlethobromide, scopine 9-hydroxy-fluorene-9-carboxylate methobromide, scopine 9-fluoro-fluorene-9-carboxyl ate methobromide, tropenol 9-methyl-fluorene-9-carboxylate methobromide, scopine 9-methyl-fluorene-9-carboxylate methobromide, cyclopropyltropine benzilate methobromide, 2,2-diphenylpropionate cyclopropyltropine methobromide, cyclopropyltropine 9-hydroxy-xanthene-9-carboxylate methobromide, cyclopropyltropine 9-methyl-fluorene-9-carboxylate methobromide, cyclopropyltropine 9-methyl-xanthene-9-carboxylate methobromide, cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide, methyl cyclopropyltropine 4,4'-difluorobenzilate methobromide, tropenol 9-hydroxy-xanthene-9-carboxylate methobromide, scopine 9-hydroxy-xanthene-9-carboxylate methobromide, tropenol 9-methyl-xanthene-9-carboxylate methobromide, scopine 9-methyl-xanthene-9-carboxylate methobromide, tropenol 9 -ethyl -x anthene- 9- carboxyl ate methobromide, tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide and scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the solvates and/or hydrates thereof.
Betamimetics which may be used are preferably selected from among albuterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reprotcrol, rimiterol, ritodrine, salmeterol, salmefamol, soterenot, sulphonterol, tiaramide, terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3 -(4- {6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzenesulphonamide, 5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-lH-quinolin-2-one, 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulphonyl}ethyl]-ainino}ethyl]-2(3H)-benzothiazolone, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-inethyl-2-butylamino]ethanol, 1-[3-(4-methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-3o butylamino}ethanol, 5-hydroxy-8-(i-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-orie, 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol and 1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.
Steroids which may be used are preferably selected from among prednisolone, prednisone, butixocortpropionate, RPR-106541, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rotleponide, ST-126, dexamethasone, (S)-fluoromethyl 6a,9a-difluoro-l7a-[(2-furanylcarbonyl)oxy]-11(3-hydroxy-16a-methyl-3-oxo-androsta-1,4-diene-17(3-carbothionate, (S)-(2-oxo-tetrahydro-furan-3S-yl) 6a,9a-difluoro-11(3-hydroxy-16a-methyl-3-oxo-l7a-propionyloxy-androsta-1,4-diene-17(3-carbothionate and etiprednol-dichloroacetate (BNP-166), optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.
PDE IV inhibitors which may be used are preferably selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), CP-325,366, BY343, D-4396 (Sch-351591), AWD-12-281 (GW-842470), N-(3,5-dichloro-l-oxo-pyridin-4-yl)-4-difluoromethoxy-cyclopropylmethoxybenzamide, NCS-613, pumafentine, (-)p-[(4aR*, I ObS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[s] [ 1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide, (R)-(+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone, 3-(cyclopentyloxy-4-methoxyphenyl)-1-(4-N'-[N-2-cyano-S-methyl-isothioureido]benzyl)-2-pyrrolidone, cis[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-l-carboxylic acid], 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-one, cis[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-ol], (R)-(+)-ethyl[4-(3-cyelopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate, (S)-(-)-ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate, CDP840, Bay-198004, D-4418, PD-168787, T-440, T-2585, arofyllin, atizoram, V-11294A, C1-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine and 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.
LTD4-antagonists which may be used are preferably selected from among montelukast, 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2- hydroxy-2-propyl)phenyl)thio)methylcyclopropane-acetic acid, 1-(((1(R)-3(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-l-methylethyl)phenyl)propyl)thio)-methyl)cyclopropane-acetic acid, pranlukast, zafirlukast, [2-[[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid, MCC-847 (ZD-3523), MN-001, MEN-(LM-1507), VUF-5078, VUF-K-8707 and L-733321, optionally in the form of the racemates, cnantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.
EGFR-kinase inhibitors which may be used are preferably selected from among cetuximab, 5 trastuzumab, ABX-EGF, Mab ICR-62, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-am] no]-1-oxo-2-buten-l-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-( {4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-1-oxo-2-buten-l-yl} amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-rnethoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-l-yl}amino)-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6- { [4-(N,N-dimethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6,7-bis-(2-methoxy-ethoxy)-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-(4-hydroxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidine, 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-l-yl]amino}-7-ethoxy-quinoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-rnethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-l-yl]amino}-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperidin-1-yl]-ethoxy} -7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-3-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-acetylamino-ethyl)-piperi din-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-ethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-l-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)am] no]-6- { 1-[(piperidin-1-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-ethansulphonylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[1-(2-methoxy-acetyl)-piperidin-4-yloxy]-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(tetrahydropyran-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4- {N-[(piperidin-l-yl)carbonyl]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxopyrrolidin-l-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(1-acetyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7(2-methoxy-ethoxy)-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[(N-methyl-N-2-methoxyethyl-amino)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-ethyl-piperi din-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, and 4-[(3-chloro-4-fluoro-phenyl)amino]-6- { 1-[(2-methoxyethyl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts thereof, the solvates and/or hydrates thereof.
By acid addition salts with pharmacologically acceptable acids which the compounds may be capable of forming are meant, for example, salts selected from among the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably the hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate.
Examples of antiallergics are: disodium cromoglycate, nedocromil.
Examples of ergot alkaloids are: dihydroergotamine, ergotamine.
Examples of substances suitable for inhalation include pharmaceutical compositions containing the above-mentioned active substances, and the salts and esters thereof and combinations of these active substances, salts and esters thereo~
The proportion of suspended drug in the finished preparation is between 0.001 and 5 %, preferably 0.005 to 3 %, particularly 0.01 to 2 %. Surface-active substances are added in amounts of from 0.01 to 10 %, preferably 0.05 to 5 %, particularly 0.05 to 3 %
(% = percent by weight).
In the case of ipratropium bromide monohydrate the suspensions according to the invention preferably contain between 0.001 to 1%, particularly 0.005 to 0.5%
ipratropium. Particularly preferred according to the invention are suspensions which contain 0.01 to 0.
1% ipratropium.
In the case of salbutamol and the salts thereof the suspensions according to the invention preferably contain between 0.005 to 5%, particularly 0.025 to 2.5% salbutamol.
Particularly preferred according to the invention are suspensions which contain 0.05 to 1%
salbutamol.
In the case of tiotropium bromide monohydrate the suspensions according to the invention preferably contain between 0.001 to 1 /o, particularly 0.0012 to 0,8%
tiotropium. Preferred according to the invention are suspensions which contain 0.002 to 0.5%, particularly preferably 0.008 to 0.4% tiotropium.
By all the active substances, e.g. tiotropium or ipratropium, is meant in each case the free ammonium cation. The propellant gas suspensions according to the invention are characterised in that they contain tiotropium or ipratropium in the form of the crystalline monohydrates. Accordingly, the present invention preferably relates to suspensions which contain crystalline tiotropium bromide monohydrate or ipratropium bromide monohydrate.
With regard to tiotropium bromide monohydrate suspensions which contain 0.001 to 0.62%, particularly preferably 0.002 to 0.5, most particularly preferably 0.002 to 0.06 of crystalline tiotropium bromide monohydrate are of particular interest.
The percentage amounts specified within the scope of the present invention are always percent by mass. If amounts by mass for tiotropium are expressed as percent by mass, the corresponding values for the crystalline tiotropium bromide monohydrate which is preferably used within the scope of the present invention may be obtained by multiplying by the conversion factor 1.2495. The same applies to ipratopium.
If anhydrous propellant gases are used, a small amount of water is added to them according to the invention. However, it is also possible according to the invention to use water-containing propellant gases, which should have a specific water content when used. This water which is added to or present in the finished suspension formulation is different from water which is chemically bound in one of the active substances or excipients. Within the scope of the present invention this non-chemically bound water is also referred to as free water, to distinguish it from the water which is molecularly or chemically bound to the active substance.
It has been found that the suspended particles of active substance change when the water content is too low. On the other hand it has been found that the particle sizes change if the water content is too high. The optimum water content may be determined individually for each substance. It has been found that the preferred amount of water in the propellant gas TG
227 ea or in mixtures of TG 227 ea with propellant gases selected from among propane, butane, pentane, dimethylether, CHC1F7,, CH2F2, CF3CH3, isobutane, isopentane and neopentane, is generally 10 to 1000 ppm, particularly preferably 50 to 500 ppm, and most particularly preferably the amount of water is 100 to 450 ppm.
In the case of fonnulations containing ipratropium bromide monohydrate with propellant gas TG 227 ea the most preferred water content of the formulation is between 20 and 500 ppm, and the water content is particularly between 50 and 350 ppm.
In the case of tiotropium bromide monohydrate the preferred water content is comparable to that for ipratropium bromide monohydrate. The most preferred range is between 50 and 230 ppm.
The percentage amounts specified within the scope of the present invention are always percent by mass. If amounts by mass for tiotropium are expressed as percent by mass, the corresponding values for the crystalline tiotropium bromide monohydrate which is preferably used within the scope of the present invention may be obtained by multiplying by the conversion factor 1.2495. The same applies to ipratopium.
If anhydrous propellant gases are used, a small amount of water is added to them according to the invention. However, it is also possible according to the invention to use water-containing propellant gases, which should have a specific water content when used. This water which is added to or present in the finished suspension formulation is different from water which is chemically bound in one of the active substances or excipients. Within the scope of the present invention this non-chemically bound water is also referred to as free water, to distinguish it from the water which is molecularly or chemically bound to the active substance.
It has been found that the suspended particles of active substance change when the water content is too low. On the other hand it has been found that the particle sizes change if the water content is too high. The optimum water content may be determined individually for each substance. It has been found that the preferred amount of water in the propellant gas TG
227 ea or in mixtures of TG 227 ea with propellant gases selected from among propane, butane, pentane, dimethylether, CHC1F7,, CH2F2, CF3CH3, isobutane, isopentane and neopentane, is generally 10 to 1000 ppm, particularly preferably 50 to 500 ppm, and most particularly preferably the amount of water is 100 to 450 ppm.
In the case of fonnulations containing ipratropium bromide monohydrate with propellant gas TG 227 ea the most preferred water content of the formulation is between 20 and 500 ppm, and the water content is particularly between 50 and 350 ppm.
In the case of tiotropium bromide monohydrate the preferred water content is comparable to that for ipratropium bromide monohydrate. The most preferred range is between 50 and 230 ppm.
It has also been found that the preferred quantity of water in the propellant gas TG 134 a or in mixtures of TG 134 a with propellant gases from the group propane, butane, pentane, dimethylether, CHC1F2, CHzF2, CF3CH3, isobutane, isopentane and neopentane is between 30 and 4000 ppm, particularly preferably between 150 and 2000 ppm and most particularly preferably between 350 and 1700 ppm.
In the case of formulations containing ipratropium monohydrate with propellant gas TG 134 a the most preferred water content of the formulation is between 70 and 1800 ppm, and in particular the water content is between 180 and 1300 ppm.
In the case of tiotropium monohydrate the preferred water content is similar to that for ipratropium bromide. The most preferred range is between 180 and 900 ppm.
If mixtures of the propellant gases TG 134 a and TG 227 ea are used, the preferred water contents are obtained from the mixing ratio of the two propellant gases.
According to the invention these amounts of water are added to the propellant gases or to the finished aerosol suspensions if the propellant gas, propellant gas mixture or the formulation does not contain any water (free water) in addition to the water chemically bound to the active substance. In the process, the water may have already been added to the propellant gas before the pharmaceutical suspension is prepared, or the pharmaceutical suspension may be prepared first with anhydrous propellant gas or propellant gas mixture and then the corresponding amount of water is added.
The amounts given in ppm are based on the liquefied propellant as the reference magnitude.
Within the scope of the present invention the term suspension formulation may be used instead of the term suspension. The two terms are to be regarded as equivalent within the scope of the present invention.
The propellant-containing inhalable aerosols or suspension formulations according to the invention may also contain other constituents such as surface-active agents (surfactants), adjuvants, antioxidants or flavourings.
The surface-active agents (surfactants) optionally present in the suspensions according to the invcntion are preferably selected from the group consisting of Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropyl myristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyl oleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monostearate, glyceryl monoricinoleate, cetylalcohol, oleyl oleate, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, ethanol and isopropanol.
Of the above-mentioned suspension adjuvants Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08 or isopropyl myristate are preferably used. Myvacet 9-45 or isopropyl myristate 5 are most preferably used.
If the suspensions according to the invention contain surfactants these are preferably used in an amount of 0.0005 - 1%, particularly preferably 0.005 - 0.5 %.
In the case of formulations containing ipratropium monohydrate with propellant gas TG 134 a the most preferred water content of the formulation is between 70 and 1800 ppm, and in particular the water content is between 180 and 1300 ppm.
In the case of tiotropium monohydrate the preferred water content is similar to that for ipratropium bromide. The most preferred range is between 180 and 900 ppm.
If mixtures of the propellant gases TG 134 a and TG 227 ea are used, the preferred water contents are obtained from the mixing ratio of the two propellant gases.
According to the invention these amounts of water are added to the propellant gases or to the finished aerosol suspensions if the propellant gas, propellant gas mixture or the formulation does not contain any water (free water) in addition to the water chemically bound to the active substance. In the process, the water may have already been added to the propellant gas before the pharmaceutical suspension is prepared, or the pharmaceutical suspension may be prepared first with anhydrous propellant gas or propellant gas mixture and then the corresponding amount of water is added.
The amounts given in ppm are based on the liquefied propellant as the reference magnitude.
Within the scope of the present invention the term suspension formulation may be used instead of the term suspension. The two terms are to be regarded as equivalent within the scope of the present invention.
The propellant-containing inhalable aerosols or suspension formulations according to the invention may also contain other constituents such as surface-active agents (surfactants), adjuvants, antioxidants or flavourings.
The surface-active agents (surfactants) optionally present in the suspensions according to the invcntion are preferably selected from the group consisting of Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropyl myristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyl oleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monostearate, glyceryl monoricinoleate, cetylalcohol, oleyl oleate, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, ethanol and isopropanol.
Of the above-mentioned suspension adjuvants Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08 or isopropyl myristate are preferably used. Myvacet 9-45 or isopropyl myristate 5 are most preferably used.
If the suspensions according to the invention contain surfactants these are preferably used in an amount of 0.0005 - 1%, particularly preferably 0.005 - 0.5 %.
10 The adjuvants optionally contained in the suspensions according to the invention are preferably selected from the group consisting of alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulphuric acid and citric acid. Ascorbic acid, phosphoric acid, hydrochloric acid or citric acid are preferably used, while hydrochloric acid or citric acid is most preferably used.
If adjuvants are present in the suspensions according to the invention, these are preferably used in an amount of 0.0001-1.0 %, preferably 0.0005-0.1 %, particularly preferably 0.001-0.01 %, while an amount of 0.001-0.005 % is particularly important according to the invention.
The antioxidants optionally contained in the suspensions according to the invention are preferably selected from the group consisting of ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbylpalmitate, while tocopherols, butylhydroxytoluene, butylhydroxyanisol or ascorbylpalmitate are preferably used.
The flavourings optionally contained in the suspensions according to the invention are preferably selected from the group consisting of peppermint, saccharine, Dentomint , aspartame and ethereal oils (for example cinnamon, aniseed, menthol, camphor), of which pepperrnint or Dentomint are particularly preferred.
With a view to administration by inhalation it is essential to provide the active substances in finely divided form. For this purpose, the active substance is obtained in finely divided form either by grinding (micronising) or using other methods known in the prior art (e.g.
precipitation, spray-drying). Methods of micronising active substances are known in the art.
Preferably after micronising the active substance has a mean particle size of 0.5 to 10 m, preferably 1 to 6 m, particularly preferably 1.5 to 5 m. Preferably at least 50%, preferably at least 60%, particularly preferably at least 70% of the particles of active substance have a particle size which is within the size ranges mentioned above. Particularly preferably at least 80%, most preferably at least 90% of the particles of active substance have a particle size which is within the size ranges mentioned above.
Surprisingly it has been found that suspensions may also be prepared which contain, in addition to the above-mentioned propellant gases, only the active substance or active substances and no other additives. Accordingly, in another aspect, the present invention relates to suspensions which contain only the active substance or active substances and no other additives.
The suspensions according to the invention may be prepared using methods known in the art.
For this, the constituents of the formulation are mixed with the propellent gas or gases (optionally at low temperatures) and filled into suitable containers.
The above-mentioned propellant-containing suspensions according to the invention may be administered using inhalers known in the art (pMDIs = pressurized metered dose inhalers).
Accordingly, in another aspect, the present invention relates to pharmaceutical compositions in the form of suspensions as hereinbefore described combined with one or more inhalers suitable for administering these suspensions. Moreover the present invention relates to inhalers, characterised in that they contain the propellant-containing suspensions according to the invention described hereinbefore.
The present invention also relates to containers (e.g. cartridges) which are fitted with a suitable valve adjusted before use with regard to the water content. The containers may be used in a suitable inhaler and contain one of the above-mentioned propellant-containing suspensions according to the invention. Suitable containers (e.g. cartridges) and processes for filling these cartridges with the propellant-containing suspensions according to the invention are known in the art.
In view of the phan-naceutical activity of anticholinergics the present invention also relates to the use of the suspensions according to the invention for preparing a pharmaceutical composition for inhalation or nasal administration, preferably for preparing a pharmaceutical composition for inhalative or nasal treatment of diseases in which anticholinergics may develop a therapeutic benefit.
If adjuvants are present in the suspensions according to the invention, these are preferably used in an amount of 0.0001-1.0 %, preferably 0.0005-0.1 %, particularly preferably 0.001-0.01 %, while an amount of 0.001-0.005 % is particularly important according to the invention.
The antioxidants optionally contained in the suspensions according to the invention are preferably selected from the group consisting of ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbylpalmitate, while tocopherols, butylhydroxytoluene, butylhydroxyanisol or ascorbylpalmitate are preferably used.
The flavourings optionally contained in the suspensions according to the invention are preferably selected from the group consisting of peppermint, saccharine, Dentomint , aspartame and ethereal oils (for example cinnamon, aniseed, menthol, camphor), of which pepperrnint or Dentomint are particularly preferred.
With a view to administration by inhalation it is essential to provide the active substances in finely divided form. For this purpose, the active substance is obtained in finely divided form either by grinding (micronising) or using other methods known in the prior art (e.g.
precipitation, spray-drying). Methods of micronising active substances are known in the art.
Preferably after micronising the active substance has a mean particle size of 0.5 to 10 m, preferably 1 to 6 m, particularly preferably 1.5 to 5 m. Preferably at least 50%, preferably at least 60%, particularly preferably at least 70% of the particles of active substance have a particle size which is within the size ranges mentioned above. Particularly preferably at least 80%, most preferably at least 90% of the particles of active substance have a particle size which is within the size ranges mentioned above.
Surprisingly it has been found that suspensions may also be prepared which contain, in addition to the above-mentioned propellant gases, only the active substance or active substances and no other additives. Accordingly, in another aspect, the present invention relates to suspensions which contain only the active substance or active substances and no other additives.
The suspensions according to the invention may be prepared using methods known in the art.
For this, the constituents of the formulation are mixed with the propellent gas or gases (optionally at low temperatures) and filled into suitable containers.
The above-mentioned propellant-containing suspensions according to the invention may be administered using inhalers known in the art (pMDIs = pressurized metered dose inhalers).
Accordingly, in another aspect, the present invention relates to pharmaceutical compositions in the form of suspensions as hereinbefore described combined with one or more inhalers suitable for administering these suspensions. Moreover the present invention relates to inhalers, characterised in that they contain the propellant-containing suspensions according to the invention described hereinbefore.
The present invention also relates to containers (e.g. cartridges) which are fitted with a suitable valve adjusted before use with regard to the water content. The containers may be used in a suitable inhaler and contain one of the above-mentioned propellant-containing suspensions according to the invention. Suitable containers (e.g. cartridges) and processes for filling these cartridges with the propellant-containing suspensions according to the invention are known in the art.
In view of the phan-naceutical activity of anticholinergics the present invention also relates to the use of the suspensions according to the invention for preparing a pharmaceutical composition for inhalation or nasal administration, preferably for preparing a pharmaceutical composition for inhalative or nasal treatment of diseases in which anticholinergics may develop a therapeutic benefit.
Particularly preferably the present invention also relates to the use of the suspensions according to the invention for preparing a pharmaceutical composition for the inhalative treatment of respiratory complaints, preferably asthma or COPD, mucoviscidosis, cystic f7ibrosis; and also systemic complaints, such as pain, migraine, high blood pressure, erectile disorders.
The Examples that follow serve to illustrate the present invention in more detail, by way of example, without restricting it to their contents.
Examples of formulations 1.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Myvacet type 9-08 (acetylated monoglyceride) 0.4 wt.%
- TG 227ea 99.5 wt.%
Total 100 wt. % (15.9 g) 2.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Isopropylmyristate 0.4 wt.%
- TG 227ea 99.5 wt.%
Total 100 wt.% (15.9 g) 3.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Tween 20 0.4 wt.%
- TG 227ea 99.5 wt.%
Total 100 wt.% (15.9 g) 4.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Tween 80 0.4 wt.%
- TG 227ea 99.5 wt.%
Total 100 wt.% (15.9 g) 5.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Isopropylmyristate 10.00 wt.%
- TG 227ea 89.90 wt.%
Total 100 wt. lo (15.9 g) 6.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Isopropylmyristate 10.00 wt.%
- Soyalecithin 0.004 wt.%
- TG 227ea 89.9 wt.%
Total 100 wt.% (15.9 g) 7.
Ipratropium bromide monohydrate 0.03 wt.%
- Salbutamol sulphate 0.19 wt.%
- Tween 20 0.4 wt.%
- TG 227ea 99.38 wt.%
Total 100 wt.% (15.9 g) 8.
- Ipratropium bromide monohydrate 0.03 wt.%
- Salbutamol sulphate 0.19 wt.%
- TG 227ea 99.78 wt.%
Total 100 wt.% (15.9 g) Fonnulation examples I to 8 preferably contain between 50 and 300 ppm water.
The Examples that follow serve to illustrate the present invention in more detail, by way of example, without restricting it to their contents.
Examples of formulations 1.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Myvacet type 9-08 (acetylated monoglyceride) 0.4 wt.%
- TG 227ea 99.5 wt.%
Total 100 wt. % (15.9 g) 2.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Isopropylmyristate 0.4 wt.%
- TG 227ea 99.5 wt.%
Total 100 wt.% (15.9 g) 3.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Tween 20 0.4 wt.%
- TG 227ea 99.5 wt.%
Total 100 wt.% (15.9 g) 4.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Tween 80 0.4 wt.%
- TG 227ea 99.5 wt.%
Total 100 wt.% (15.9 g) 5.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Isopropylmyristate 10.00 wt.%
- TG 227ea 89.90 wt.%
Total 100 wt. lo (15.9 g) 6.
- Ipratropium bromide monohydrate 0.03 wt.%
- Fenoterol hydrobromide 0.07 wt.%
- Isopropylmyristate 10.00 wt.%
- Soyalecithin 0.004 wt.%
- TG 227ea 89.9 wt.%
Total 100 wt.% (15.9 g) 7.
Ipratropium bromide monohydrate 0.03 wt.%
- Salbutamol sulphate 0.19 wt.%
- Tween 20 0.4 wt.%
- TG 227ea 99.38 wt.%
Total 100 wt.% (15.9 g) 8.
- Ipratropium bromide monohydrate 0.03 wt.%
- Salbutamol sulphate 0.19 wt.%
- TG 227ea 99.78 wt.%
Total 100 wt.% (15.9 g) Fonnulation examples I to 8 preferably contain between 50 and 300 ppm water.
9.
- Ipratropium bromide monohydrate 0.04 wt.%
- Salbutamol sulphate 0.21 wt.%
- TG 134a 99.75 wt.%
Total 100 wt.% (14.8 g) Formulation example 9 may contain between 200 and 1000 ppm water.
- Ipratropium bromide monohydrate 0.04 wt.%
- Salbutamol sulphate 0.21 wt.%
- TG 134a 99.75 wt.%
Total 100 wt.% (14.8 g) Formulation example 9 may contain between 200 and 1000 ppm water.
Claims (18)
1) Propellant-containing aerosol suspension containing particles of active substance with chemically bound water, at least 85 wt.% of a propellant gas or a propellant gas mixture with TG 227 ea and/or TG 134 a or in admixture with at least one other propellant gas selected from among propane, butane, pentane, dimethylether, CHC1F2, CH2F2, CF3CH3, isobutane, isopentane and neopentane, characterised in that the aerosol suspension contains additional free water in addition to the water chemically bound to the active substance.
2) Aerosol suspension according to claim 1, characterised in that it contains crystalline particles of active substance which bind the water as water of crystallisation, hydrate or complex.
3) Aerosol suspension according to claim 1I or 2, characterised in that the active substance selected from among the betamimetics, anticholinergics, steroids, antiallergics, derivatives of ergot alkaloids, triptanes, CGRP-antagonists, phosphodiesterase-V
inhibitors, phosphodiesterase-IV inhibitors, LTD4-antagonists, EGFR-kinase inhibitors, and combinations of such active substances.
inhibitors, phosphodiesterase-IV inhibitors, LTD4-antagonists, EGFR-kinase inhibitors, and combinations of such active substances.
4) Aerosol suspension according to claim 3, characterised in that the suspension contains an anticholinergic as active substance, preferably ipratropium salt or tiotropium salt, more preferably ipratropium bromide or tiotropium bromide, particularly preferably ipratropium bromide monohydrate or tiotropium bromide monohydrate.
5) Aerosol suspension according to one of the preceding claims, characterised in that the amount of active substance is between 0.001 and 5 %, preferably 0.002 to 3 %, particularly 0.002 to 2 %.
6) Aerosolsuspension according to one of the preceding claims, characterised in that, for the propellant gas 227 ea or mixtures with this propellant gas, the amount of water is between and 1000 ppm, particularly preferably between 50 and 500 ppm and most particularly preferably between 100 and 450 ppm.
7) Aerosol supension according to one of the preceding claims, characterised in that, for the propellant gas 134 a or mixtures with this propellant gas, the amount of water is between 30 and 4000 ppm, particularly preferably between 150 and 2000 ppm and most particularly preferably between 350 and 1700 ppm.
8) Aerosol suspension according to one of the preceding claims, characterised in that it contains as further ingredients surface-active substances (surfactants), adjuvants, antioxidants and/or flavourings.
9) Aerosol suspension according to one of the preceding claims, characterised in that it contains as surface-active substances (surfactants) one or more compounds selected from among Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropyl myristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyl oleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monostearate, glyceryl monoricinoleate, cetylalcohol, oleyloleate, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, ethanol and isopropanol
10) Aerosol suspension according to one of the preceding claims, characterised in that it contains as adjuvants one or more compounds selected from among alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulphuric acid and citric acid.
11) Aerosol suspension according to one of the preceding claims, characterised in that it contains as antioxidants one or more compounds selected from among ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbylpalmitate.
12) Aerosol suspension according to one of the preceding claims, characterised in that it contains no other ingredients in addition to the active substance, water and the propellant gas or gases.
13) Use of an aerosol suspension according to one of claims 1 to 12 for preparing a pharmaceutical composition, preferably for preparing a pharmaceutical composition for the treatment, by inhalation or optionally by nasal route, of diseases in which anticholinergics may confer a therapeutic benefit.
14) Use according to claim 13, characterised in that the diseases are respiratory complaints, preferably asthma, COPD, mucoviscidosis or cystic fibrosis.
15) Use according to one or more of claims 1-13, characterised in that the disease is a systemic complaint, preferably pain, migraine, hypertension or erectile disorder.
16) Process for preparing aerosol suspensions according to one of claims 1 to 12, characterised in that water-containing propellant gas or propellant gas mixture is used to prepare the aerosol suspension.
17) Process for preparing aerosol suspensions according to one of claims 1 to 12, characterised in that an aerosol suspension is prepared with anhydrous propellant gas or propellant gas mixture and then water is added.
18) Container for filling with a propellant-containing aerosol according to one or more of claims 1-12, characterised in that the container contains a suitable valve which is adjusted before use in relation to its water content.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004032322A DE102004032322A1 (en) | 2004-07-02 | 2004-07-02 | Propellant-containing aerosol suspension useful for treating diseases e.g. asthma, pain contains active substance with chemically bound water, propellant gas or its mixture |
| DE102004032322.4 | 2004-07-02 | ||
| DE102005023334.1 | 2005-05-17 | ||
| DE200510023334 DE102005023334A1 (en) | 2005-05-17 | 2005-05-17 | Propellant-containing aerosol suspension useful for treating diseases e.g. asthma, pain contains active substance with chemically bound water, propellant gas or its mixture |
| PCT/EP2005/006865 WO2006002840A2 (en) | 2004-07-02 | 2005-06-25 | Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2571519A1 true CA2571519A1 (en) | 2006-01-12 |
| CA2571519C CA2571519C (en) | 2013-05-14 |
Family
ID=35169696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2571519A Expired - Fee Related CA2571519C (en) | 2004-07-02 | 2005-06-25 | Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8357352B2 (en) |
| EP (1) | EP1809243B2 (en) |
| JP (1) | JP5209963B2 (en) |
| KR (1) | KR101297061B1 (en) |
| AR (1) | AR049660A1 (en) |
| AU (1) | AU2005259523B2 (en) |
| BR (1) | BRPI0512878A (en) |
| CA (1) | CA2571519C (en) |
| DK (1) | DK1809243T4 (en) |
| EA (1) | EA013428B1 (en) |
| EC (1) | ECSP077126A (en) |
| ES (1) | ES2391563T5 (en) |
| IL (1) | IL180461A0 (en) |
| MX (1) | MXPA06015204A (en) |
| NO (1) | NO20070373L (en) |
| NZ (1) | NZ552869A (en) |
| PL (1) | PL1809243T5 (en) |
| TW (1) | TWI377943B (en) |
| WO (1) | WO2006002840A2 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2571519C (en) | 2004-07-02 | 2013-05-14 | Boehringer Ingelheim International Gmbh | Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant |
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| DE102006053374A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical formulation for aerosols with two or more active substances and at least one surface-active substance |
| DE102006017320A1 (en) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant |
| US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| WO2008047239A2 (en) * | 2006-09-21 | 2008-04-24 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| GB2442745B (en) | 2006-10-13 | 2011-04-06 | At & T Corp | Method and apparatus for acoustic sensing using multiple optical pulses |
| GB2442746B (en) | 2006-10-13 | 2011-04-06 | At & T Corp | Method and apparatus for acoustic sensing using multiple optical pulses |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| AU2010210620B2 (en) * | 2009-02-03 | 2016-02-25 | Microbion Corporation | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| EP2414560B1 (en) | 2009-03-31 | 2013-10-23 | Boehringer Ingelheim International GmbH | Method for coating a surface of a component |
| JP5763053B2 (en) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adapter, inhaler and atomizer |
| EA026241B1 (en) | 2009-11-25 | 2017-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Nebulizer |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| EP2504051B1 (en) | 2009-11-25 | 2019-09-04 | Boehringer Ingelheim International GmbH | Nebulizer |
| US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2012130757A1 (en) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medical device comprising a container |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| JP6335798B2 (en) | 2012-02-28 | 2018-05-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New propellant-containing tiotropium formulation |
| WO2013152894A1 (en) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Atomiser with coding means |
| EP3030298B1 (en) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Nebulizer |
| ES2836977T3 (en) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizer |
| WO2015169430A1 (en) | 2014-05-07 | 2015-11-12 | Boehringer Ingelheim International Gmbh | Nebulizer |
| PL3139979T3 (en) | 2014-05-07 | 2023-12-27 | Boehringer Ingelheim International Gmbh | Unit, nebulizer and method |
| MX2016014403A (en) | 2014-05-07 | 2017-01-20 | Boehringer Ingelheim Int | Container, indicator device, and nebulizer. |
| US10322198B2 (en) | 2016-07-08 | 2019-06-18 | The Procter & Gamble Company | Freshening compositions comprising isopropyl myristate |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8824804D0 (en) * | 1988-10-22 | 1988-11-30 | Fisons Plc | Device |
| US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| DE4003270A1 (en) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS |
| US5919435A (en) * | 1990-11-09 | 1999-07-06 | Glaxo Group Limited | Aerosol formulation containing a particulate medicament |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB9202519D0 (en) † | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
| RO117414B1 (en) | 1992-12-09 | 2002-03-29 | Jager Paul D Waterbury | Pharmaceutical composition of gas dispersoid in solution |
| EP0960830A1 (en) * | 1993-04-30 | 1999-12-01 | Minnesota Mining And Manufacturing Company | Seal configuration for aerosol canister |
| JP3172190B2 (en) * | 1993-07-15 | 2001-06-04 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Instrument for dispensing pharmaceutical aerosol |
| CA2218179A1 (en) * | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for beclomethasone dipropionate |
| GB9513084D0 (en) * | 1995-06-27 | 1995-08-30 | Bespak Plc | Dispensing apparatus |
| SE9701750D0 (en) * | 1997-05-12 | 1997-05-12 | Astra Pharma Prod | Inhalation device and method of manufacture thereof |
| US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| GB2326334A (en) | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
| JP3801348B2 (en) | 1997-07-28 | 2006-07-26 | 株式会社ヴァレオサーマルシステムズ | Receiver tank |
| JP4117059B2 (en) * | 1998-02-10 | 2008-07-09 | 東洋エアゾール工業株式会社 | High concentration powder aerosol products |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| PT1102579E (en) * | 1998-08-04 | 2003-07-31 | Jago Res Ag | MEDICINAL AEROSOL FORMULATIONS |
| US5955958A (en) † | 1998-10-05 | 1999-09-21 | Lu; Kai | Holiday candy jar with light and sound effects |
| IT1303788B1 (en) | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | MEDICINAL AEROSOL FORMULATIONS. |
| DZ2947A1 (en) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Pressure metered dose inhaler. |
| US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
| US6739333B1 (en) * | 1999-05-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Stainless steel canister for propellant-driven metering aerosols |
| GB0002798D0 (en) * | 2000-02-09 | 2000-03-29 | Glaxo Group Ltd | Actuator nozzle for metered dose inhaler |
| WO2002005785A1 (en) * | 2000-07-18 | 2002-01-24 | Aeropharm Technology Incorporated | Modulated release therapeutic aerosols |
| EP1311294A2 (en) * | 2000-08-04 | 2003-05-21 | Longwood Pharmaceutical Research, Inc. | Formulations of mometasone and a bronchodilator for pulmonary administration |
| DE10043509A1 (en) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Solid peptide preparations for inhalation and their manufacture |
| US7776315B2 (en) * | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| EP1241113A1 (en) | 2001-03-12 | 2002-09-18 | CHIESI FARMACEUTICI S.p.A. | Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
| EP1414508B1 (en) | 2001-06-26 | 2011-04-20 | Norton Healthcare Limited | An improved aerosol actuator |
| BR0307235A (en) * | 2002-02-01 | 2004-12-07 | Atrazeneca Ab | Inhalation composition |
| EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
| EP3536344B1 (en) * | 2002-03-01 | 2020-02-19 | Chiesi Farmaceutici S.p.A. | Formoterol superfine formulation |
| DE10214263A1 (en) † | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA suspension formulations containing an anticholinergic |
| EP1565422B1 (en) * | 2002-11-22 | 2009-02-04 | Eli Lilly And Company | Vitamin d receptor modulators |
| EA009087B1 (en) * | 2003-03-20 | 2007-10-26 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants |
| AR041873A1 (en) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | A PHARMACEUTICAL FORMULATION IN ADEQUATE AEROSOL FOR ORAL OR NASAL INHALATION CONTAINING GLUCOCORTICOIDS IN A STABLE SOLUTION TO STORAGE; A METHOD FOR STABILIZING FORMULATIONS AND USE OF A STABILIZING AGENT |
| DE102004032322A1 (en) | 2004-07-02 | 2006-02-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Propellant-containing aerosol suspension useful for treating diseases e.g. asthma, pain contains active substance with chemically bound water, propellant gas or its mixture |
| CA2571519C (en) | 2004-07-02 | 2013-05-14 | Boehringer Ingelheim International Gmbh | Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant |
| BRPI0517204A (en) | 2004-12-17 | 2008-09-30 | Cipla Ltd | crystalline levosalbutamol sulfate (form i), crystalline levosalbutamol sulfate (form ii), crystalline levosalbutamol sulfate (form iii), process for preparing crystalline levosalbutamol sulfate form i, process for preparing crystalline levosalbutamol sulfate form ii , process for preparing levosalbutamol sulfate form iii, pharmaceutical composition, compound, combination, dry inhaler powder, process for preparing a dry inhaler powder, process for preparing a pharmaceutical composition, process for manufacturing a pharmaceutical composition, method for treatment of a mammal, and use of a combination of salbutamol |
| DE102006053374A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical formulation for aerosols with two or more active substances and at least one surface-active substance |
| DE102006017320A1 (en) * | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant |
-
2005
- 2005-06-25 CA CA2571519A patent/CA2571519C/en not_active Expired - Fee Related
- 2005-06-25 MX MXPA06015204A patent/MXPA06015204A/en active IP Right Grant
- 2005-06-25 EP EP05761637.7A patent/EP1809243B2/en active Active
- 2005-06-25 AU AU2005259523A patent/AU2005259523B2/en active Active
- 2005-06-25 DK DK05761637.7T patent/DK1809243T4/en active
- 2005-06-25 ES ES05761637T patent/ES2391563T5/en active Active
- 2005-06-25 EA EA200700042A patent/EA013428B1/en not_active IP Right Cessation
- 2005-06-25 WO PCT/EP2005/006865 patent/WO2006002840A2/en active Application Filing
- 2005-06-25 NZ NZ552869A patent/NZ552869A/en unknown
- 2005-06-25 BR BRPI0512878-1A patent/BRPI0512878A/en not_active IP Right Cessation
- 2005-06-25 KR KR1020077002760A patent/KR101297061B1/en active IP Right Grant
- 2005-06-25 PL PL05761637.7T patent/PL1809243T5/en unknown
- 2005-06-25 JP JP2007518518A patent/JP5209963B2/en active Active
- 2005-06-29 US US11/169,876 patent/US8357352B2/en active Active
- 2005-07-01 AR ARP050102757A patent/AR049660A1/en unknown
- 2005-07-01 TW TW094122245A patent/TWI377943B/en active
-
2006
- 2006-12-31 IL IL180461A patent/IL180461A0/en unknown
-
2007
- 2007-01-02 EC EC2007007126A patent/ECSP077126A/en unknown
- 2007-01-19 NO NO20070373A patent/NO20070373L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006002840A2 (en) | 2006-01-12 |
| TWI377943B (en) | 2012-12-01 |
| CA2571519C (en) | 2013-05-14 |
| EP1809243A2 (en) | 2007-07-25 |
| MXPA06015204A (en) | 2007-03-15 |
| NO20070373L (en) | 2007-01-31 |
| KR101297061B1 (en) | 2013-08-19 |
| EP1809243B2 (en) | 2022-06-08 |
| WO2006002840A8 (en) | 2012-11-08 |
| AU2005259523B2 (en) | 2011-06-09 |
| BRPI0512878A (en) | 2008-04-15 |
| TW200612945A (en) | 2006-05-01 |
| EP1809243B1 (en) | 2012-07-18 |
| KR20070042166A (en) | 2007-04-20 |
| JP5209963B2 (en) | 2013-06-12 |
| WO2006002840A3 (en) | 2006-11-16 |
| EP1809243B8 (en) | 2013-02-27 |
| PL1809243T3 (en) | 2013-05-31 |
| PL1809243T5 (en) | 2022-12-27 |
| ES2391563T5 (en) | 2022-10-26 |
| JP2008504325A (en) | 2008-02-14 |
| EA013428B1 (en) | 2010-04-30 |
| DK1809243T4 (en) | 2022-09-05 |
| AR049660A1 (en) | 2006-08-23 |
| NZ552869A (en) | 2010-06-25 |
| US8357352B2 (en) | 2013-01-22 |
| EA200700042A1 (en) | 2007-08-31 |
| IL180461A0 (en) | 2007-06-03 |
| ECSP077126A (en) | 2007-02-28 |
| DK1809243T3 (en) | 2012-10-15 |
| ES2391563T3 (en) | 2012-11-27 |
| US20060002863A1 (en) | 2006-01-05 |
| AU2005259523A1 (en) | 2006-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8357352B2 (en) | Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant | |
| AU2007213819B2 (en) | Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant | |
| US20090029990A1 (en) | Dihydropteridinones in the treatment of respiratory diseases | |
| CA2652697C (en) | Inhalant propellant-free aerosol formulation | |
| DE102006017320A1 (en) | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant | |
| US20060286041A1 (en) | Mrp iv inhibitors for the treatment of respiratory diseases | |
| CA2637533A1 (en) | Adapter for inhalation appliances for treatment of artificially ventilated patients | |
| DE102006014433A1 (en) | Metered aerosols for the administration of pharmaceutical preparations | |
| CA2578449C (en) | Novel powder inhalation preparations based on modified lactose blends that are used as adjuvants | |
| US7658949B2 (en) | Surface modification of lactose excipient for use in powders for inhalation | |
| DE102005023334A1 (en) | Propellant-containing aerosol suspension useful for treating diseases e.g. asthma, pain contains active substance with chemically bound water, propellant gas or its mixture | |
| DE102006009599A1 (en) | Propellant gas absorption with MDIs with packaging | |
| MX2008009323A (en) | Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |